Pioneering Regenerative Medicine
Without Immunosuppression

We are a data-driven and patient-centric regenerative medicine company working to enable implantable tissue, organoid or cell therapy without the requirement for life-long immunosuppression. Leveraging our proprietary technology platform, we are advancing a pipeline of product candidates that have the potential to cure diseases.

Pioneering Regenerative Medicine
Without Immunosuppression

We are a data-driven and patient-centric regenerative medicine company working to enable implantable tissue, organoid or cell therapy without the requirement for life-long immunosuppression. Leveraging our proprietary technology platform, we are advancing a pipeline of product candidates that have the potential to cure diseases.

iTOL-100:

Biotechnology-Derived Protein Inducing
Immune Tolerance Platform

iTOL-100 is a synthetic form of the naturally occurring protein, FasL, combined with a synthetic biotin-PEG microgel (SA-FasL microgel) that allows convenient and effective co-administration with implanted cells or organoids to induce local immune tolerance without the need for life-long immunosuppression.

iTOL-100:

Biotechnology-Derived Protein Inducing
Immune Tolerance Platform

iTOL-100 is a synthetic form of the naturally occurring protein, FasL, combined with a synthetic biotin-PEG microgel (SA-FasL microgel) that allows convenient and effective co-administration with implanted cells or organoids to induce local immune tolerance without the need for life-long immunosuppression.

Developing a Potential Cure for Type 1 Diabetes

Our lead program iTOL-101 is being developed as a potential cure for Type 1 Diabetes and in a pre-clinical non-human primate study, pancreatic islet cells co-implanted with iTOL-101 exhibited long-term function with control of blood glucose levels and restoration of insulin secretion without the use of chronic immune suppression. Our second lead candidate, iTOL-102, is leveraging significant advancements in stem cells to derive pancreatic islets which allows an inexhaustible supply of insulin-producing cells for use in Type 1 Diabetes.

Development Pipeline

Email Alerts:

Have the latest news and information delivered directly to your inbox

Get in Touch with us:

Please reach out with any questions

News:

Email Alerts:

Have the latest news and information delivered directly to your inbox

Get in Touch with us:

Please reach out with any questions

News: